STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients - Candlesense
STRAT Coverage

STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients

Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment

Related Questions

How could this development affect analyst sentiment and target price for STRATA's stock? What are the potential regulatory or compliance considerations related to the expanded CPT code and coverage? How might the new coverage affect STRATA's partnership or licensing agreements with insurers and healthcare providers? Will the expanded coverage lead to changes in STRATA's pricing strategy or reimbursement rates? How does STRATA's market opportunity and coverage expansion compare to its competitors in the dermatology and laser therapy space? How will the expanded CPT code and accelerated Medicare and private payer coverage affect STRATA's revenue forecasts? How will the validation of Excimer Laser efficacy in vitiligo influence STRATA's product adoption rates? What is the expected timeline for achieving the increased addressable market of 30M+ patients? What are the potential risks or uncertainties associated with the coverage expansion and market expansion? What impact could the accelerated coverage have on STRATA's cash flow and profitability in the short and long term?
Find similar articles on Candlesense globenewswire